Is there an Indian version of Sunitinib?

Sunitinib (Sunitinib) has an Indian version, which is a generic drug. Its pharmaceutical ingredients are basically the same as those of the original sunitinib drug, but the manufacturers and prices are different. Sunitinib is an oral, multi-target inhibitor of tyrosine kinases, vascular endothelial growth factor receptor and platelet-derived growth factor receptor) and direct cancer-promoting pathways (such as stem cell factor receptor and FMS-like tyrosine kinase-3).

Preclinical investigational agents have shown that it exhibits strong inhibitory activity against these targets. Clinical trial results demonstrate the therapeutic potential of this drug and implicate sunitinib in the pathophysiology of malignancies such as renal cell carcinoma and gastrointestinal stromal tumor. Sunitinib is a multikinase inhibitor indicated for the treatment of gastrointestinal stromal tumors, advanced renal cell carcinoma, and progressive well-differentiated pancreatic neuroendocrine tumors in patients with unresectable, locally advanced, or metastatic disease following disease progression or intolerance to imatinib mesylate. Sunitinib is available in a generic form as a capsule.

The original sunitinib drug has been launched in China and has entered the scope of Class B medical insurance. SpecificationsThe price of 12.5mg*28 tablets is around RMB 3,500. The original sunitinib drug has also been launched overseas. The price of 12.5mg*7 tablets is around RMB 1,500 (the price may fluctuate due to the exchange rate). There are also generic drugs produced in other countries. The price of 12.5mg*28 tablets produced by an Indian pharmaceutical factory is around RMB 750 (the price may fluctuate due to the exchange rate). There may be differences in the prices of different specifications of drugs.